drugset / Trial / NCT04087460
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
Phase 0
Completed
120 enrolled
CanSino Biologics Inc.
Henan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Infections with Streptococcus pneumoniae often cause serious health problems, especially for infants and the elderly.Failure to cover all polysaccharide types is an even greater problem with adults than with children. The aim of the study is to preliminary evaluate the safety and immunogenicity of PBPV vaccine compared to placebo,in order to provide a basis for subsequent clinical trial design.
Timeline
- Start
- 2020-04-10
- Primary completion
- 2021-05-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Protein based pneumococcal vaccine | Vaccine | 20 ug | Intramuscular |
| Subject | Protein based pneumococcal vaccine | Vaccine | 50 ug | Intramuscular |
| Subject | Protein based pneumococcal vaccine | Vaccine | 100 ug | Intramuscular |